<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686643</url>
  </required_header>
  <id_info>
    <org_study_id>AGSAVI1705</org_study_id>
    <nct_id>NCT04686643</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 study to evaluate efficacy and safety of AGSAVI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of&#xD;
      AGSAVI for Inadequately Controlled with AGLS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitSBP at week 10</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting diastolic blood pressure at week 4 and week 10</measure>
    <time_frame>week 4 and week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure at week 4</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢Proportion of subjects achieving Blood Pressure control</measure>
    <time_frame>week 4 and week 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGSAVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AGLS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSAVI</intervention_name>
    <description>S-amlodipine, Valsartan, Indapamide</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>S-amlodipine, Valsartan, Indapamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGLS</intervention_name>
    <description>S-amlodipine, Valsartan</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>S-amlodipine, Valsartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hypertension patient who satisfied below condition at Visit 1.&#xD;
&#xD;
               -  patient who takes antihypertensive drug&#xD;
&#xD;
                    -  140mmHg &lt;= sitSBP &lt;= 200mmHg&#xD;
&#xD;
               -  patient who doesn't take antihypertensive drug&#xD;
&#xD;
                    -  160mmHg &lt;= sitSBP &lt;= 200mmHg&#xD;
&#xD;
          -  Hypertension patient who satisfied below condition at Visit 2.&#xD;
&#xD;
               -  140mmHg &lt;= sitSBP &lt;= 200mmHg at Visit 2&#xD;
&#xD;
               -  130mmHg &lt;= sitSBP &lt;= 200mmHg at Visit 2(In high-risk patients)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who have received 4 or more antihypertensive drug&#xD;
&#xD;
          -  Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between&#xD;
             2 times of BP measuring at Visit 1&#xD;
&#xD;
          -  Patient with sitDBP &gt;= 120mmHg at Visit 1 or 2&#xD;
&#xD;
          -  Patient with secondary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

